drugset / Trial / NCT05297292
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to compare the efficacy and safety of MW02 versus Lucentis in the treatment of neovascular age-related macular degeneration.The study was divided into two stages. The first stage was to explore the dose and the second stage was to explore the frequency of administration.
Timeline
- Start
- 2021-05-07
- Primary completion
- 2023-05-15
- Completion
- 2024-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MW02 | Monoclonal antibody | 1 mg | Intravitreal |
| Subject | MW02 | Monoclonal antibody | 1.5 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |